Pacylex Pharmaceuticals, Inc.

3:15 PM - 3:30 PM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
Pacylex is a Canadian oncology company exploiting a new discovery in cancer biology which may explain how some cancers arise from normal cells. The company is responding to this discovery by developing a first-in-class, oral drug, PCLX-001, to turn on selective lethality, apoptosis, in these cancer cells, while leaving normal cells unharmed. Animal tests show this drug candidate completely eliminates tumors in xenograft models of leukemias and lymphomas. PCLX-001 also kills many solid tumor cancer cell lines and retards tumor growth in some PDX models of human lung and breast cancer.

Pacylex is part of the new Merck-sponsored Accelerator in Edmonton. A Note investment round is funding studies necessary to file an IND in early 2020 for PCLX-001. Our potent activity against malignant lymphocytes and in acute leukemia coupled with the absence of bone marrow and lymphocyte toxicity in 14-day tox studies in 2 species suggest a therapeutic index consistent with a solid clinical candidate.
Company Type:
Company Website:
Company HQ State:
Alberta
Company HQ Country:
Canada
Year Founded:
2014
Main Therapeutic Focus:
Lead Product in Development:
PCLX-001
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
photo
CEO
Pacylex Pharmaceuticals, Inc.